Roche Holding AG (RHHVF)

285.30 +1.30 (+0.46%) At close: 03:45PM EST

Roche Holding AG

Grenzacherstrasse 124
Basel 4058
Switzerland
41 61 688 11 11
https://www.roche.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 103,613

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Severin Schwan Ph.D.	Executive Chairman	8.58M	N/A	1967
Dr. Thomas Schinecker	Chief Executive Officer	4.42M	N/A	1975
Dr. Alan Hippe	Chief Financial & Information Officer	4.69M	N/A	1967
Ms. Cristina A. Wilbur	Chief People Officer	3.34M	N/A	1967
Dr. Johannes Carolus Clevers M.D., Ph.D.	Head of Roche Pharma Research & Early Development	94.22k	N/A	1957
Dr. Bruno Eschli	Head of Investor Relations	N/A	N/A	N/A
Ms. Claudia Bockstiegel	General Counsel	N/A	N/A	1964
Ms. Pascale Schmidt	Chief Compliance Officer	N/A	N/A	1973
Ms. Barbara Schadler	Head of Group Communications	N/A	N/A	1962
Dr. Nicolas Dunant	Head of Group Media Relations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD); and strategic agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize zilebesiran. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate governance

Roche Holding AG’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.